<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02612558</url>
  </required_header>
  <id_info>
    <org_study_id>C-935788-053</org_study_id>
    <nct_id>NCT02612558</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)</brief_title>
  <acronym>SOAR</acronym>
  <official_title>A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigel Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigel Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether fostamatinib is safe and effective in
      treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin response</measure>
    <time_frame>by Week 12</time_frame>
    <description>Hemoglobin level of &gt; 10 g/dL and 2 g/dL higher than the baseline hemoglobin</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Warm Antibody Autoimmune Hemolytic Anemia</condition>
  <arm_group>
    <arm_group_label>Fostamatinib 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fostamatinib 150 mg bid (morning and evening) over the course of 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib 150 mg bid</intervention_name>
    <description>Fostamatinib 150 mg bid. The dose of Fostamatinib may be reduced at any time to as low as 100 mg PO once daily (qd) if dose limiting adverse events are observed</description>
    <arm_group_label>Fostamatinib 150 mg</arm_group_label>
    <other_name>R935788</other_name>
    <other_name>R788</other_name>
    <other_name>Fostamatinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subject must have had a diagnosis of primary or secondary warm antibody AIHA.

        - Must have failed at least 1 prior treatment regimen for AIHA.

        Exclusion Criteria:

          -  Subject with cold antibody AIHA, cold agglutinin syndrome, mixed type AIHA, or
             paroxysmal cold hemoglobinuria.

          -  Subject with a platelet count of &lt; 30,000/μL.

          -  Subject has AIHA secondary to autoimmune disease, including systemic lupus
             erythematosis (SLE), or lymphoid malignancy and the underlying disease is not stable
             or is not well-controlled on current therapy.

          -  Subject has uncontrolled or poorly controlled hypertension, defined as systolic blood
             pressure ≥ 140 mmHg, or diastolic blood pressure ≥ 90 mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rigel Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Rigel Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rigel Pharmaceuticals, Inc. Rigel Pharmaceuticals</last_name>
    <email>clinicaltrials@rigel.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Boxer, MD</last_name>
      <phone>520-866-0206</phone>
      <email>michael.boxer@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Julie Klinker</last_name>
      <phone>520-269-3821</phone>
      <email>julie.klinker@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Boxer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richy Agajanian, MD</last_name>
      <phone>562-693-4477</phone>
      <email>ragajanian@icrinstitute.com</email>
    </contact>
    <contact_backup>
      <last_name>Kirsten Bettino</last_name>
      <phone>562-693-4477</phone>
      <email>kbettino@airesearch.us</email>
    </contact_backup>
    <investigator>
      <last_name>Richy Agajanian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Choi, MD</last_name>
      <phone>858-534-1765</phone>
      <email>mychoi@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Ivers</last_name>
      <phone>858-822-6281</phone>
      <email>bivers@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Broome, MD</last_name>
      <phone>202-444-8240</phone>
      <email>catherine.m.broome@gunet.georgetown.edu</email>
    </contact>
    <contact_backup>
      <last_name>Bradford Simmons</last_name>
      <phone>202-687-0116</phone>
      <email>bradford.simmons@georgetown.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Catherine Broome, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Kuter, MD</last_name>
      <phone>617-726-8033</phone>
      <email>kuter.david@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jan Sjoquist</last_name>
      <phone>617-726-0153</phone>
      <email>JSJOQUIST@MGH.HARVARD.EDU</email>
    </contact_backup>
    <investigator>
      <last_name>David Kuter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Murakhovskaya, MD</last_name>
      <phone>718-920-4137</phone>
      <email>imurakho@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Elena Crouch</last_name>
      <phone>718-430-2145</phone>
      <email>elena.crouch@einstein.yu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Irina Murakhovskaya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brody School of Medicine at East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darla Liles, MD</last_name>
      <phone>252-744-0282</phone>
      <email>lilesd@ecu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Devika Srivastava</last_name>
      <phone>252-744-5837</phone>
      <email>srivastavad15@ecu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Darla Liles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>W.G. &quot;Bill&quot; Hefner VA Medical Center</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Agnew, MD</last_name>
      <phone>704-638-9000</phone>
      <phone_ext>5037</phone_ext>
      <email>Elizabeth.Agnew@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Stacy Dobbs</last_name>
      <phone>704-638-9000</phone>
      <phone_ext>5045</phone_ext>
      <email>Stacy.Dobbs@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Elizabeth Agnew, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Lichtin, MD</last_name>
      <phone>216-444-6823</phone>
      <email>lichtia@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Lindsey Clark</last_name>
      <phone>216-445-9048</phone>
      <email>clarkl@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Alan Lichtin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerry Rogers, MD</last_name>
      <phone>614-366-9338</phone>
      <email>kerry.rogers@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Clare Stevens</last_name>
      <phone>614-685-2055</phone>
      <email>Clare.Stevens@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kerry Rogers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology San Antonio Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Lyons, MD</last_name>
      <phone>210-595-5626</phone>
      <email>roger.lyons@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Todora, BSN, RN</last_name>
      <phone>210-595-5694</phone>
      <email>Jennifer.Todora@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Roger Lyons, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George M Rodgers III, MD</last_name>
      <phone>801-213-2016</phone>
      <email>george.rodgers@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Renee Rinaldi</last_name>
      <phone>801-585-5341</phone>
      <email>renee.rinaldi@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>George M Rodgers III, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Field, MD</last_name>
      <phone>414-937-3848</phone>
      <email>Joshua.Field@BCW.edu</email>
    </contact>
    <contact_backup>
      <last_name>Zora Jovanovic</last_name>
      <phone>414-937-6457</phone>
      <email>Zora.Jovanic@BCW.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joshua Field, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences- McMaster University Medical Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Arnold, MD</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>28603</phone_ext>
      <email>arnold@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Erin Jamula</last_name>
      <phone>905-525-1940</phone>
      <phone_ext>1845</phone_ext>
      <email>jamulae@mcmaster.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Donald Arnold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.aihastudy.com</url>
    <description>www.aihastudy.com</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2015</study_first_submitted>
  <study_first_submitted_qc>November 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2015</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Warm antibody autoimmune hemolytic anemia (AIHA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Autoantibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

